GlassScriptPhysician profile
Mohammed A Kassem
NPI 1023053808
$9,532.78
in general payments reported to CMS, 2019-2025
50 companies · $1,347 in 2025
The $1,347 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,795 · 2020: $809 · 2021: $1,024 · 2022: $1,387 · 2023: $1,278 · 2024: $1,891 · 2025: $1,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,516.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,175.98 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Genentech USA, INC. | $1,013.98 | 2019-2024 | Phesgo, Perjeta, Kadcyla |
| E.R. Squibb & Sons, L.L.C. | $730.01 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $602.77 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Lilly USA, LLC | $560.85 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $487.05 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Amgen INC. | $412.28 | 2019-2024 | Prolia, Evenity, Lumakras |
| Novartis Pharmaceuticals Corporation | $370.91 | 2019-2025 | |
| Seagen INC. | $343.51 | 2019-2023 | Tukysa |
| Incyte Corporation | $326.69 | 2019-2025 | Jakafi |
| Janssen Biotech, INC. | $311.43 | 2021-2025 | Erleada, Balversa, Akeega |
| Pfizer INC. | $296.71 | 2019-2025 | |
| Genzyme Corporation | $280.77 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $277.67 | 2019-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Servier Pharmaceuticals LLC | $190.73 | 2023-2025 |
Show all 49 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Kassem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.